Table 1.
Baseline demographic and clinical characteristics.
| Characteristic | SOF + DCV ± RBV (n = 176) | SOF + SMV ± RBV (n = 79) | Total (n = 255) |
|---|---|---|---|
| Male, n (%) | 103 (58.5%) | 38 (48.1%)a | 141 (55.2%)a |
| Mean (SD) age, years | 58.1 (±10.3) | 57.1 (±12.4) | 57.8 (±10.8) |
| HCV genotype | |||
| 1 total | 102 (57.9%) | 79 (100.0%) | 198 (66.8%) |
| 1 unspecified | 26 (14.7%) | 8 (10.1%) | 34 (13.3%) |
| 1a | 36 (20.4%) | 39 (49.3%) | 75 (29.4%) |
| 1b | 40 (22.7%) | 31 (39.2%) | 71 (27.8%) |
| 3 | 72 (41.0%) | – | 72 (28.2%) |
| Missing data | 2 (1.1%) | 1 (1.2%) | 3 (1.1%) |
| Viral load ≥ 800,000 IU mL−1, n (%) | 89 (50.5%) | 37 (46.8%) | 126 (49.4%) |
| Missing data | 9 (5.1%) | 2 (2.5%) | 11 (4.3%) |
| Treatment experience, n (%) | 92 (52.2%) | 35 (44.3%) | 127 (49.8%) |
| Missing data | 1 (0.5%) | 3 (3.7%) | 4 (1.5%) |
| Fibrosis stage, n (%) | |||
| F0–F3 | 38 (21.5%) | 32 (40.5%) | 70 (27.4%)b |
| F4 (cirrhotic) | 77 (43.7%) | 22 (27.8%) | 99 (38.8%)b |
| Missing data | 61 (34.6%) | 25 (31.6%) | 86 (33.7%) |
| Liver transplantation | 5 (2.8%) | 3 (3.7%) | 8 (3.1%) |
| Treatment duration, n (%) | |||
| 12 weeks | 129 (73.0%)a | 77 (97.4%) | 206 (80.7%)a,b |
| 24 weeks | 44 (25.0%) | 2 (2.5%) | 46 (18.0%)b |
| Addition of RBV, n (%) | 56 (31.8%) | 8 (10.1%) | 64 (25.0%) |
| Co-infection | |||
| Hepatitis B virus (HBV) | 4 (2.2%) | 1 (1.2%) | 5 (1.9%) |
| Human immunodeficiency virus (HIV) | 10 (5.6%) | – | 10 (13.9%) |
a
1 patient missing data.
b
p < 0.05 (comparison between number of patients in each group that received sofosbuvir with daclatasvir versus sofosbuvir with simeprevir). Abbreviations: DAA, direct acting antivirals; DCV, daclatasvir; IFN, interferon; HCV, hepatitis C virus; LED, ledipasvir; RBV, ribavirin; SD, standard deviation; SMV, simeprevir; SOF, sofosbuvir.